ClinicalTrials.Veeva

Menu
E

East Coast Institute for Research | Jacksonville, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tirzepatide
LY3298176
Empagliflozin
Orforglipron
BI 456906
LY900014
Apixaban
BI 690517
Bococizumab
LY3502970

Parent organization

This site is a part of East Coast Institute for Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

21 of 75 total trials

A Study in Patients with Mixed Dyslipidemia

A Phase 2 in Patients With Mixed Dyslipidemia

Enrolling
Mixed Dyslipidemia
Drug: BW-00112

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-rela...

Active, not recruiting
Overweight or Obesity
Overweight
Drug: Placebo
Drug: Orforglipron

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult part...

Active, not recruiting
Overweight
Obesity
Drug: Orforglipron
Drug: Placebo

The goal of this clinical trial is to learn about the effect of the study drug (ZT-01) on low blood sugar (hypoglycemia) in adults with type 1 diabet...

Enrolling
Type 1 Diabetes Mellitus with Hypoglycemia
Drug: Placebo
Drug: ZT-01, 22 mg

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 d...

Active, not recruiting
Obesity
Diabetes Mellitus, Type 2
Drug: Survodutide
Drug: Placebo

This study is open to adults who are at least 18 years old and have* a body mass index (BMI) of 30 kg/m² or more, or* a BMI of 27 kg/m² or more and a...

Active, not recruiting
Obesity
Drug: survodutide
Drug: Placebo

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People ca...

Begins enrollment this month
Heart Failure
Drug: Placebo matching vicadrostat
Drug: Empagliflozin

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left...

Enrolling
Heart Failure
Drug: vicadrostat
Drug: Empagliflozin

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and eleva...

Active, not recruiting
Cardiovascular Disease and Lipoprotein(a)
Drug: TQJ230
Drug: Placebo
Locations recently updated

AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Rou...

Enrolling
Post Bariatric Hypoglycemia
Drug: Avexitide
Other: Placebo

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalm...

Active, not recruiting
Glaucoma
Ocular Hypertension
Drug: Rhopressa®
Drug: T4090 0.3%

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Enrolling
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: Enlicitide Decanoate

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Olpasiran
Drug: Placebo

The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in...

Enrolling
Diabetes Mellitus, Type 1
Drug: Lispro
Drug: HDV-Lispro

Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucom...

Enrolling
Open-Angle Glaucoma
Device: XEN45 (Glaucoma Gel Stent)

Trial sponsors

Lilly logo
Boehringer Ingelheim logo
Merck Sharp & Dohme (MSD) logo
Pfizer logo
Medtronic logo
Amgen logo
Medtronic logo
M
N
Novartis logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems